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Abstract 
Background: To assess the effect on malaria prevalence, village specific monthly administrations of pyrimethamine, 
chlorproguanil, chloroquine or placebo were given to children in four previously treatment-naïve Liberian villages, 
1976–78. Plasmodium falciparum in vivo resistance developed to pyrimethamine only. Selection of molecular markers 
of P. falciparum resistance after 2 years of treatment are reported.
Methods: Blood samples were collected from 191 study children in a survey in 1978. Polymorphisms in pfcrt, pfmdr1, 
pfdhfr, pfdhps, pfmrp1 and pfnhe1 genes were determined using PCR-based methods.
Results: Pfcrt 72–76 CVIET was found in one chloroquine village sample, all remaining samples had pfcrt CVMNK. 
Pfmdr1 N86 prevalence was 100%. A pfmdr1 T1069ACT→ACG synonymous polymorphism was found in 30% of chloro-
quine village samples and 3% of other samples (P = 0.008). Variations in pfnhe1 block I were found in all except the 
chloroquine treated village (P < 0.001). Resistance associated pfdhfr 108N prevalence was 2% in the pyrimethamine 
village compared to 45–65% elsewhere, including the placebo village (P = 0.001).
Conclusions: Chloroquine treatment possibly resulted in the development of pfcrt 72–76 CVIET. Selection of pfmdr1 
T1069ACG and a pfnhe1 block 1 genotypes indicates that chloroquine treatment exerted a selective pressure on P. falci-
parum. Pyrimethamine resistance associated pfdhfr 108N was present prior to the introduction of any drug. Decreased 
pfdhfr 108N frequency concurrent with development of pyrimethamine resistance suggests a non-pfdhfr polymor-
phisms mediated resistance mechanism.
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Background
Plasmodium falciparum has historically shown consid-
erable ability to develop resistance to antimalarial drugs. 
Increased malaria specific morbidity and mortality have 
been associated with development and spread of quinine 
(QN), chloroquine (CQ) and sulfadoxine–pyrimethamine 
(SP) resistance. Reports of resistance to the currently rec-
ommended artemisinin-based combination therapy are 
consequently of major concern and highlight the impor-
tance of understanding the evolution of drug resistance 
[1–6].
At least fifteen single nucleotide polymorphisms (SNP) 
in the P. falciparum chloroquine resistance transporter 
(pfcrt) gene have been associated with CQ resistance in 
field isolates [7–9]. Specific haplotypes at positions 72–76 
have been linked to regional evolution of CQ resist-
ance and the 76T allele appears essential for resistance 
Open Access
Malaria Journal
*Correspondence:  irina.jovel@ki.se 
1 Malaria Research, Department of Microbiology, Tumour and Cell Biology, 
Karolinska Institutet, Stockholm, Sweden
Full list of author information is available at the end of the article
Page 2 of 8Jovel et al. Malar J  (2017) 16:113 
[10–12]. Drug resistance associated SNPs have also been 
identified in the multidrug resistance gene 1 (pfmdr1) 
including N86Y, Y184F, S1034C, N1042D, F1226Y and 
D1246Y. Various combinations of these SNPs have been 
shown to modulate levels of drug resistance/tolerance 
to QN, CQ, amodiaquine, mefloquine and lumefantrine 
[13].
The P. falciparum Na+/H+ exchanger 1 gene (pfnhe1) 
has been associated with QN resistance [14, 15]. Specifi-
cally,  >1 DNNND repeat and one DDNHNDNHNND 
repeat in the coding microsatellite ms4760 have been 
associated with reduced in  vivo QN sensitivity [14, 16, 
17]. The function of pfnhe1 has not been fully deter-
mined, but it has been proposed that it actively effluxes 
protons to maintain a pH of 7.4 within the parasite [18]. 
Pfnhe1 has also been suggested to play a role in CQ 
resistance [19, 20], but this was subsequently disputed 
[21, 22].
Pyrimethamine (PYR) resistance has been associated 
with polymorphisms A16V, N51I, C59R, S108N/T and 
I164L in P. falciparum dihydrofolate reductase (pfdhfr). 
Typically, an initial S108N change that is considered to 
be essential for PYR resistance occurs, causing a 7- to 
50-fold increase of IC 50 in vitro. Accumulation of addi-
tional SNPs further increases IC 50 [23, 24]. Similarly, 
P. falciparum dihydropteroate synthase (pfdhps) SNPs 
S436F/A, A437G, K540E, A581G and A613S have been 
associated with sulphadoxine resistance. The A437G 
substitution appears to be the first step for resistance to 
sulphadoxine and addition of 540E, 436F/A, 581G and 
613S further enhance resistance [25]. Quintuple pfdhfr 
51I/59R/108N and pfdhps 437G/540E have been shown 
to result in highly sulphadoxine–pyrimethamine (SP) 
resistant parasites [26, 27]. The R1466K SNP of P. falci-
parum multi drug resistance protein 1 (pfmrp1) has also 
been associated with recrudescence after treatment with 
SP [28].
The aim of this study was to determine possible early 
P. falciparum in  vivo selection of genetic markers asso-
ciated with antimalarial drug resistance after repeated 
exposure to CQ, PYR or chlorproguanil (CPGN). A large 
field study conducted between 1976 and 1978 in four vil-
lages in northern Liberia where virtually no anti-malar-
ials had been previously used was therefore revisited 
[29]. Children aged 2–9  years received monthly admin-
istrations of CQ, PYR, CPGN or placebo depending upon 
which village they lived in. One drug was consistently 
used in each village. During the study period P. falcipa-
rum developed in  vivo resistance to PYR and partially 
reduced susceptibility to CPGN whilst CQ remained 
effective [29–31]. The in  vivo drug susceptibilities were 
assessed as Day 7 clearance of parasitaemia by micros-
copy after single doses of 10 mg/kg CQ, 2 mg/kg PYR or 
1.5 mg/kg CPGN respectively. For CQ the clearance rates 
were 100% among children in CQ village and the control 
village. For PYR the clearance rates were 7% among chil-
dren in PYR village and 96% in the control village. For 
CPGN the clearance rates were 53% among children in 
CPGN village and 96% in the control village. Sequence 
variation in pfcrt, pfmdr1, pfnhe1, pfmrp1, pfdhfr and 
pfdhps in samples collected after 2 years of monthly pre-
sumptive treatment with either CQ, PYR, CPGN or pla-
cebo were determined.
Methods
Study area
The clinical study from which samples were used was 
conducted in a rural area of northern Liberia 25–35 km 
from Yekepa. Four villages, about 5 km from each other, 
were included in the study: Bondi, Baytonwee, Bonah and 
Kinon. Each village had around 500 inhabitants. The vil-
lages were separated by dense forest, which made access 
to and between the villages difficult. Access to healthcare 
and specifically anti-malarial treatment was very limited 
when the study started in 1976. The climate is tropical 
with a dry season from November to April and a rainy 
season from May to October. The temperature is gener-
ally between 21 and 32  °C. Malaria was holoendemic 
when the clinical study was conducted [29, 30]. In 1976 
(prior to deployment of monthly presumptive treatment) 
the overall parasite prevalence in the study area assessed 
by blood slide microscopy in 2–9 years old children was 
82% for P. falciparum, 39% for Plasmodium malariae and 
9% for Plasmodium ovale [32].
Study group, consent, drug administration, sample 
collection and storage
Children 2–9 years old, present in the villages in Novem-
ber 1976 were invited to participate in the study. All 
(n  =  282) agreed to participate after verbal informed 
consent. The four villages were visited every 14  days 
for 3 years. Children were given single dose anti-malar-
ial drugs every 4  weeks for 2  years as follows. Bondi: 
8–15  mg base/kg dose of CQ. Baytonwee: 1.0–2.0  mg 
base/kg of CPGN. Bonah: 1.3–2.5  mg base/kg of PYR. 
Kinon: 1 or 2 tablets of Vitamin B (placebo). Drug intake 
was supervised by the investigators [29].
Children in all villages were also treated with 8–15 mg/
kg base of single dose CQ in case of fever and confirmed 
malaria infection throughout the two-year study period. 
At the time this was considered a therapeutic dose of CQ 
[29]. After 2  years of monthly presumptive treatment, 
capillary whole blood samples were collected 4–6 weeks 
after last intake of study drug (i.e. from 28th of Febru-
ary to 17th of March, 1978) from all children (n = 191) 
present and still included in the study. The children were 
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now 4–11  years old. Samples were coded and stored at 
−20  °C. The prevalence of P. falciparum in each treated 
village, as assessed by microscopy, was 23% (CQ), 94% 
(PYR), 73% (CPGN) and 88% (placebo) [29], whereas P. 
malariae and P. ovale were rarely detected.
The study was approved by the Liberian Institute of 
Biomedical Research [29]. Molecular analyses were 
approved by the Stockholm regional ethics board (refer-
ence number: 2013/836-32).
Molecular analysis
DNA was extracted using QIAamp Blood Mini Kit (QIA-
gen Biosciences, Germantown, MD, USA). The samples 
were extracted separately from other samples in our 
research laboratory to minimise the risk of contamina-
tion. Extracted DNA was stored at −20 °C until use.
Pfcrt 72–76, pfmdr1 1034–1246, pfdhfr 16–185, 
pfdhps 436–632 and pfnhe1 ms4760 haplotypes were 
identified by PCR amplification followed by sequenc-
ing using previously described PCR protocols [12, 16, 
33–35]. The Sequencher™ software version 4.6 (Gene 
Codes Corporation, Ann Arbor, MI, USA) was used 
for sequence analyses. The P. falciparum 3D7 clone 
sequence obtained from the NCBI database was used 
as references for pfcrt (Accession no. NC_004328), 
pfmdr1 (Accession no. XM_001351751.1), pfdhfr 
(Accession no. XM_001351443.1) pfdhps (Acces-
sion no. XM_001349382.1) and pfnhe1 (Accession no. 
XM_001349726). Pfnhe1 ms4760 sequences were also 
compared with previously described isolates and clones 
[16, 36].
In addition to sequencing PCR–RFLP (restriction frag-
ment length polymorphism) was used to identify the 
following SNPs; pfcrt K76T, A220S, Q271E, N326D/S, 
I356L/T, R371I, pfdhfr N51I, C59R, S108T/N, pfdhps 
S436F/A, A437G and K540E and pfmdr1 N86Y and 
Y184F using previously described methods [12, 37, 38]. 
The pfmrp1 allele K1466R was determined by pyrose-
quencing [28].
PCR and restriction products were resolved on 2% 
agarose gels (Amresco, Solon, OH, USA). All gels were 
stained with a nucleic acid gel stain (GelRed™, Biotium 
Inc. Hayward, CA, USA) and visualized under UV tran-
sillumination (GelDoc®, Biorad, Hercules, CA, USA). 
PCR products were purified and sequenced commercially 
(Macrogen Inc. Seoul, Korea).
Statistics
Data were entered, validated and analysed on Microsoft 
Excel 2003 and StataCorp 12. Allele proportions were 
calculated by dividing the number of samples with a cer-
tain allele by the number of samples with an identifiable 
allele at that position. Thus mixed infections contrib-
uted to the proportion of both alleles. Associations were 
determined using Fishers Exact test using StataCorp 12.
Results
A total of 191 samples were included in the study, of 
which 50, 48, 48 and 45 were from the CQ, PYR, CPGN 
and placebo village, respectively. At least one SNP was 
identified in all samples (not only microscopy positive) 
and each SNP was identified in 81–98% of samples. Neg-
ative controls were used throughout without any signs of 
contamination.
Pfcrt
Pfcrt K76 was found in 185/186 (99%) samples. A sin-
gle sample carrying pfcrt 76T was detected in the vil-
lage using CQ. The CVMNK haplotype was found in 
177/178 (99%) successfully sequenced samples and the 
CVIET haplotype was found in the sample that had pfcrt 
76T by RFLP. The pfcrt CVIET result was confirmed by 
PCR–RFLP and sequencing after re-extracting the sam-
ple alone. The pfcrt haplotype at codons 220, 271, 326, 
356 and 371 was determined in the CQ and placebo vil-
lages only. The wild type AQNIR haplotype was found in 
all successfully amplified samples (88/95 [93%]) including 
the sample with the pfcrt CVIET haplotype.
Pfmdr1
Pfmdr1 N86 was found in all 161 (100%) successfully 
amplified samples. Pfmdr1 Y184 was found in 75/160 
(47%), 184F in 47/160 (29%) and Y184+184F in 38/160 
(24%). The ratio of 184F was non-significantly higher 
in the CPGN (19/37 [51%]), PYR (27/46 [59%]) and CQ 
(19/33 [58%]) villages compared to the placebo village 
(20/44 [45%]). Similarly, no significant difference was 
observed in Y184 ratio in the CPGN (22/37 [59%]), PYR 
(32/46 [70%]), CQ (20/33 [61%]) villages compared with 
the placebo village (29/44 [66%]). Excluding mixed infec-
tions did not alter the findings significantly.
The pfmdr1 S1034C, N1042D, F1226Y and D1246Y 
haplotypes were SNFD in all 163 (100%) success-
fully sequenced samples. The frequency of a synony-
mous SNP at codon 1069 (ACT→ACG) was found to 
be significantly higher in the CQ village (11/17 [30%]) 
compared to the PYR (3/45, P  =  0.008), CPGN (1/38, 
P  =  0.001) and placebo (1/43, P  =  0.001) villages. 
Three novel synonymous SNPs 1061 (GAT→GAC), 
1137 (TCA→TCC) and 1185 (ATT→ATC) were found 
in 1, 4 and 2 of the 163 samples, respectively. Two 
novel non synonymous SNPs 1166 (GGA→GCA) and 
1190 (GAT→AAT) were found in 2 and 1 samples, 
respectively.
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Pfnhe‑1
Pfnhe1 ms4760 was successfully amplified in 156/191 
(82%) samples. Eight of the 114 previously described 
pfnhe1 haplotypes [16, 36] and 47 novel ms4760 haplo-
types were found. The haplotypes found are shown in 
Additional file  1: Table S1. Of the 47 new haplotypes, 
32 consisted of variation in Block I. Proportions of sam-
ples with haplotypes in block I are presented in Table 1. 
Variation in pfnhe1 block I were significantly more com-
mon in the villages using CPGN (9/35 [26%], P < 0.001), 
PYR (18/44 [41%], P < 0.001) and placebo (16/39 [41%], 
P  <  0.001) compared to the CQ treated village (0/38). 
Though Block I did not vary in the CQ village 10 differ-
ent ms4760 haplotypes were identified due to variations 
in other parts of ms4760.
The ratio of ms4760 haplotypes in successfully amplified 
samples were significantly lower in the villages using CQ 
(10/38 [26%], P  =  0.006) but non-significantly lower in 
the villages using CPGN (13/35 [37%], P = 0.07) and PYR 
19/44 (43%, P = 0.19) compared to placebo 23/39 (59%).
The number of quinine resistance associated 
DDNHNDNHNND repeats in block V were one in 
30/156 (19%), two in 124/156 (80%) and 3 in 2/156 (1%) 
samples. The distributions of repeats were similar in all 
villages. There were no associations of variations in block 
I or V and any SNPs in pfmdr1, pfdhfr or pfdhps.
Pfdhfr
Allele proportions are presented in Table  2. The pro-
portion of the PYR resistance associated 108N was sig-
nificantly lower in the village using PYR (1/46 [2%]) 
compared to the villages using CPGN (17/39 [44%], 
P  <  0.001), CQ (18/39 [46%], P  <  0.001) and placebo 
(29/45 [64%], P < 0.001). The other codons found were all 
A16, N51, C59 and I164 that are associated with sensitiv-
ity to PYR.
Pfdhps
Allele proportions are presented in Table 3. The sulphad-
oxine resistance associated pfdhps 613S was found in 10% 
(14/135) of samples in this sulphadoxine–pyrimethamine 
naïve area. No other resistance associated polymor-
phisms were found. The proportion of pfdhps 613S was 
significantly lower in the PYR village (0/38) compared to 
the village using CQ (7/26 [27%], P = 0.001) and non-sig-
nificantly lower in the villages using CPGN (3/31 [10%], 
P = 0.09) and placebo (4/39 [10%], P = 0.12). When data 
from the CPGN, CQ and placebo villages were pooled 
Table 1 Pfnhe-1 ms4760 types
Resistance associated alleles are shown in italics
a Previously described ms4760-1, -3, -4, -5, -7, -28, -98 and Mali_15 with no variation in block I
b ms4760 haplotypes Lib_01 to Lib_15 with no variation in block I
c ms4760 haplotypes Lib_19 to Lib_47 with variation in block I
d The frequency of samples with no variation in block I was higher in the CQ treated village compared with the frequencies in the villages treated with CPGN 
(P = 0.028), PYR (P = 0.001), placebo (P = 0.068) and with pooled data from all villages (P = 0.001)
e The frequency of samples with variation in block I was lower in the CQ treated village when compared with separate and pooled frequencies from the other villages 
(P < 0.001)
ms4760 haplotype Chlorproguanil Pyrimethamine Chloroquine Vitamin B Total
Number of previously described ms4760 haplotypes with no variation in block 
Ia
22 25 25 17 89
Number of novel ms4760 haplotypes with no variation in block Ib 4 2 13d 6 25
Number of novel ms4760 haplotypes with variation in block Ic 9 17 0e 16 42
Total no. of different haplotypes 13 29 10 23 55
Total no. of samples 35 44 38 39 156
Table 2 Allele frequencies at resistance associated pfdhfr codons 16, 51, 59, 108 and 164
Resistance associated alleles are shown in italics
a The frequency of samples with the resistance associated pfdhfr 108N was lower in the pyrimethamine treated village when compared with separate and pooled 
frequencies from the other villages (P < 0.001)
Village A16 N51 C59 S108 108N 108S+N I164
Chlorproguanil 36/36 36/36 36/36 21/39 (54%) 17/39 (45%) 1/39 (3%) 39/39
Pyrimethamine 41/41 41/41 41/41 45/46 (98%) 1/46 (2%)a 0 44/44
Chloroquine 31/31 31/31 31/31 21/39 (54%) 18/39 (46%) 0 36/36
Vitamin B 39/39 39/39 39/39 15/45 (33%) 29/45 (65%) 1/45 (2%) 40/40
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the findings were significantly different compared with 
the PYR village (P = 0.01).
Pfmrp1
Pfmrp1 R1466 (wild type) was found in 137/137 (100%) 
successfully amplified samples.
Discussion
This study provides a unique insight into the early 
appearance of genetic markers associated with anti-
malarial drug resistance and their selection 2 years after 
monthly presumptive treatment with CQ, PYR and CPG 
or placebo in a previously virtually anti-malarial treat-
ment-naïve area of Liberia.
One sample had the pfcrt 76T SNP in the 72-76 CVIET 
haplotype not previously recorded in Africa as early as 
1978. Pfcrt CVIET was confirmed by repeated PCR anal-
yses on re-extracted DNA several months after the first 
analyses. Contamination is, therefore, unlikely to explain 
this remarkable finding. Throughout the world pfcrt 76T 
has been linked to CQ resistance within various pfcrt 
72–76 haplotypes. By 1978, pfcrt CVIET had existed in 
Southeast Asia for many years but not in Africa. Molec-
ular analysis has shown that the CVIET later found 
throughout Africa was derived from this Southeast Asian 
lineage [8]. Southeast Asian pfcrt typically have addi-
tional downstream SNPs at codons 220, 271, 326, 356 and 
371. Our sample had those typical among African origin 
CQ sensitive genotypes (and 3D7) [39]. Furthermore, the 
study area was very isolated making importation unlikely. 
The most likely explanation is thus that pfcrt 72–76 
CVIET arose in the CQ study village de-novo following 
a period of intermittent presumptive treatment with CQ.
Irrespective of how this isolated CVIET haplotype 
came to be in the study area it did not seem to have 
become widespread as only pfcrt CVMNK parasites were 
found in 50 samples collected 3  years later in the same 
area [40]. This observation is consistent with longitudi-
nal surveillance of high in vivo efficacy and in vitro sus-
ceptibility to CQ in Bondi (CQ village) between 1976 and 
1978 [29, 41]. In the ordered evolution of pfcrt SNPs that 
eventually give rise to CQ resistance described by Sum-
mers et al. [42], having CVIET alone with no other pfcrt 
SNPs only resulted in a small increase in Pfcrt’s ability to 
transport CQ and hence to confer resistance [42]. Fur-
thermore, these mutations interfere with haemoglobin 
digestion resulting in a loss of fitness [43]. Thus CVIET 
might have developed in Liberia but did not become 
widespread as it provided only weak selective advantage 
in this holoendemic area.
The increased frequency of the synonymous SNP 
pfmdr1 T1069ACG and decreased diversity in pfnhe1 block 
I in the CQ treated village indicates that CQ exerted a 
selective pressure on the drug-naïve parasite popula-
tion. In line with this both genes have previously been 
linked to CQ resistance [19, 20] and previously described 
block I ms4760 haplotypes in samples collected after the 
spread of CQ resistance had the same block I type as that 
selected for in the CQ village [36]. However, as pfmdr1 
T1069ACG is a synonymous SNP it was not selected itself 
but is probably a marker for selection of a parasite strain 
or a pfmdr1 genotype that had a survival advantage when 
CQ was used.
Decreased in  vitro and in  vivo QN susceptibility has 
been associated with the pfnhe1 ms4760-1 haplotype 
that has two DNNND and one DDNHNDNHNND 
and with having more than one DNNND repeat and 
one DDNHNDNHNND repeat in some studies but not 
in others [14, 16, 36, 44]. Though QN was not used in 
the Yekepa area at the time of this study the frequency 
of pfnhe1 ms4760-1 (26%) was similar to the frequency 
found at day 0 in a recent study in Mali where ms4760-1 
was associated with decreased QN susceptibility [16]. 
Considering the geographic separation of Liberia and 
Mali results should be compared with considerable cau-
tion. However, similar frequencies found in Liberia in 
1978, prior to a drug selective pressure and in Mali and 
Senegal several decades later suggest that ms4760-1 has 
not been under a strong selective pressure.
The PYR resistance associated pfdhfr 108N was sur-
prisingly not selected for in the PYR village despite 
development of in  vivo resistance to PYR within a year 
Table 3 Allele frequencies at resistance associated pfdhps codons 436, 437, 514, 540, 581 and 613
Resistance associated alleles are shown in italics
a The frequency of samples with the resistance associated pfdhps 613S was lower in the pyrimethamine treated village compared to pooled frequencies from the 
other villages (P < 0.01) and the village using CQ (P = 0.001)
Village S436 A437 I514 K540 A581 A613 613S
Chlorproguanil 40/40 40/40 32/32 32/32 32/32 29/32 (91%) 3 (9%)
Pyrimethamine 38/38 38/38 38/38 38/38 38/38 38/38 0a
Chloroquine 30/30 30/30 26/26 26/26 26/26 19/26 (73%) 7(27%)
Vitamin B 40/40 40/40 40/40 40/40 40/40 35/39 (90%) 4 (10%)
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of initiating monthly intermittent presumptive therapy 
[29]. In contrast it was found at significant frequen-
cies in the placebo and CQ villages where no antifolate 
drugs had been used, suggesting that it was a wild type 
in Liberia in 1978. Similarly, resistance associated pfdhfr 
51I, 59R, 108N were found in 9/66 samples collected in 
The Gambia in 1984 prior to widespread use of SP [45]. 
These intriguing results suggest that there may have been 
an alternate mechanism of PYR resistance in our study 
village as has previously been suggested [13, 46]. Further-
more, the 108N did not provide a selective advantage in 
the presence of this alternate mechanism but rather the 
opposite. Amplifications of the pfdhfr or GTP-cyclo-
hydrolase (gch1) genes have been linked to PYR resist-
ance in the past [47, 48]. Gene amplifications could have 
occurred in Liberia and might thus constitute an early 
method of PYR resistance in line with the correlation 
between pfmdr1 amplifications and drug resistance to 
mefloquine and artemisinin derivatives [49]. An alter-
native mechanism of PYR resistance might be a greater 
influx of folate into the parasite as has been suggested to 
be mediated by pfmrp1 1466K [28]. However, in Liberia 
only pfmrp1 R1466 was found. Concerning pfdhps, PYR 
is not likely to directly exert a selective effect, yet the fre-
quency of pfdhps 613S (that is related to sulphadoxine 
resistance) was lower in the PYR treated village. Perhaps 
this represents an indirect effect of selection of other 
genes.
Chlorproguanil (CPGN) is believed to be a DHFR 
inhibitor that is partly metabolized to the probably more 
P. falciparum active chlorcycloguanil in vivo. In line with 
this parasites with pfdhfr 16V and 108T and 108N have 
been associated with decreased susceptibility to the 
structurally similar cycloguanil in vitro and ex vivo, [26, 
50–52]. Finding no difference in pfdhfr 108N frequency 
in the CPGN village compared with the placebo vil-
lage indicates that 108 N was not the cause of the partly 
reduced CPGN susceptibility seen in the study area [29].
Conclusion
Unique data on the effect of monthly intermittent pre-
sumptive CQ, PYR and CPGN therapy on selection of 
known resistance genes in previously treatment-naïve 
P. falciparum populations is presented. The pfcrt 72–76 
haplotype CVIET was detected in the CQ village and 
possibly developed de-novo. However, none of the down-
stream pfcrt SNPs commonly found throughout CQR 
genotypes in Africa today were detected. Decreased 
variation of pfnhe1 was seen and a synonymous pfmdr1 
1069T SNP was selected detected in the CQ village sug-
gesting that CQ exerted a selective pressure on the drug 
naïve parasite population. The PYR resistance associated 
SNP pfdhfr 108N was highly prevalent in this antifolate 
naïve parasite population and intriguingly deselected 
concomitant with emergence of PYR resistance suggest-
ing alternative mechanisms of PYR resistance. The results 
provide new insights into the evolution of anti-malarial 
drug resistance in Africa.
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